Longitudinal cognitive assessment using the Cumulus NeuLogiq platform in amyotrophic lateral sclerosis and...

People living with ALS (plwALS) and/or FTD (plwFTD) often experience cognitive and behavioural changes. However, detection can be confounded due to factors like fatigue and testing anxiety. Cumulus neuroscience developed NeuLogiq^(R), a multi-modal neurocognitive platform that can be used in clinic or at home, providing an ecologically valid measure of cognition. This study examined the feasibility and usability of NeuLogiq in plwALS, plwFTD, and controls, and compared performance on gold standard neuropsychological assessments with corresponding NeuLogiq digital assessments. Over 8 months, plwALS (n = 11), plwFTD (n = 7), and matched healthy controls (n = 10) completed longitudinal full neuropsychological assessment, as well as three 25-minute NeuLogiq Platform sessions every 2 weeks in their homes. Participants adhered well to the study schedule, conducting over 32/54 sessions on average. All groups rated usability in the 'good' or 'excellent' range and had > 80% complete data. Baseline group differences were detectable on both NeuLogiq digital assessments and benchmark neuropsychological assessments of similar cognitive domains. Longitudinal mixed effects models found that the ALS group showed decline on NeuLogiq measures of emotion recognition and speech fluency. These findings suggest that the NeuLogiq platform is feasible and usable for plwALS and plwFTD, and can identify cognitive deficits to a similar extent as benchmark assessments over time.